Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin + NAC + Romiplostim in Steroid-Resistant/Relapsed ITP
NCT07662525Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of atorvastatin, acetylcysteine and romiplostim in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Primary endpoint: Sustained Response off-Treatment rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
atorvastatinacetylcysteineromiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07662525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662525.